Market brief

European Diagnostics Landscape 2026: IVD, Liquid Biopsy, Molecular, Digital Pathology

European diagnostics in 2026 is a wide sector covering molecular IVD, liquid biopsy, digital pathology AI, point-of-care testing, genetic screening, reproductive health, and national laboratory services. The Memel Biotech directory surfaces 47 diagnostics operators across 10 countries. Finland (9) leads by operator count with a concentration of molecular and infectious-disease diagnostics plus Wallac / Revvity for neonatal screening. Poland (7) hosts Warsaw / Wroclaw / Krakow clusters and the national Diagnostyka laboratory network. Sweden (6) and Germany (6) add liquid biopsy and molecular IVD operators. Denmark (5) contributes digital pathology and molecular diagnostics. Lithuania (5) anchors Baltic diagnostics alongside Estonia (2) and Latvia (2). The directory covers established IVD operators (QIAGEN, altona Diagnostics, Wallac/Revvity), clinical-stage innovators (Elypta, Biovica, SAGA Diagnostics, Hummingbird), and AI + platform operators (Aiforia, Visiopharm, Ligence).

Summary

Key findings

Finland holds 9 diagnostics operators in the directory - the highest country count - spanning molecular IVD (Abacus Diagnostica, Aidian, ArcDia, Wallac / Revvity), digital pathology AI (Aiforia Technologies), gastrointestinal diagnostics (Biohit), point-of-care (Bone Index), and wearable medical devices (Adamant Health).
Liquid biopsy and cancer-monitoring diagnostics is a Swedish + Danish + German specialty the directory surfaces at clinical-stage and commercial scope: Elypta (Solna), Biovica (Uppsala), SAGA Diagnostics (Lund), 2cureX (Copenhagen), GLX Analytix (Copenhagen), MethylDetect (Aalborg), Hummingbird Diagnostics (Heidelberg), Mainz Biomed (Mainz).
Digital pathology + AI-assisted image analysis concentrates in three operators the directory surfaces: Aiforia Technologies (Helsinki), Visiopharm (Horsholm), and Ligence (Kaunas, cardiac imaging AI).
National and multi-site clinical laboratory networks operate from Poland (Diagnostyka - Krakow-headquartered, national scope), Latvia (E. Gulbis Laboratory - Riga, nationwide), and Estonia (Synlab Estonia - Tallinn, pan-European network presence).
First-pass shortlist

Choose the diagnostic route before choosing a company

An IVD manufacturer, a clinical laboratory, a liquid-biopsy developer, an AI software company, and a reagent supplier have different regulatory and commercial roles. These entries are source-backed starting points, not proof of regulatory clearance, clinical availability, or an open partnership route.

Molecular IVD or point-of-care product

Assays, instruments, or sample-to-answer systems

Germany, Finland, Denmark, Poland, and Sweden

Publicly stated scope
Start with QIAGEN, altona Diagnostics, Aidian, Abacus Diagnostica, ArcDia, Spindiag, Genomtec, or IDL Diagnostics according to the assay, platform, and testing setting.
Confirm first
Intended use, geography, CE-IVD or research-use status, specimen type, workflow, throughput, integration, procurement model, and country-specific availability.
Do not assume
That an IVD or PCR product description confirms a cleared test for the indication, local reimbursement, or use in the intended clinical workflow.
Clinical laboratory service

Testing through a national or multi-site laboratory network

Poland, Latvia, and Estonia

Publicly stated scope
Start with Diagnostyka, E. Gulbis Laboratory, or Synlab Estonia when the need is laboratory-delivered testing rather than buying an assay or device.
Confirm first
Test menu, accredited location, sample logistics, turnaround time, data-transfer requirements, patient-consent and privacy responsibilities, and contracting entity.
Do not assume
That a laboratory network offers every assay, country, or trial-central-lab service without a specific service agreement.
Liquid biopsy or oncology biomarker collaboration

Cancer-monitoring, biomarker, or functional-testing developer

Sweden, Denmark, and Germany

Publicly stated scope
Treat Elypta, Biovica, SAGA Diagnostics, Hummingbird Diagnostics, Mainz Biomed, 2cureX, and GLX Analytix as technology or clinical-collaboration candidates based on their disclosed programmes.
Confirm first
Clinical evidence, intended use, cohort and sample requirements, validation stage, regulatory status, data rights, geography, and whether the relevant collaboration route is open.
Do not assume
That a public biomarker platform is commercially available, reimbursed, or suitable for a specific clinical decision without validation.
AI pathology or imaging software

Decision-support or image-analysis platform

Finland, Denmark, and Lithuania

Publicly stated scope
Start with Aiforia or Visiopharm for publicly described digital pathology and tissue-image workflows, or Ligence for cardiac imaging AI rather than pathology.
Confirm first
Clinical versus research use, intended workflow, regulatory status, interoperability, local validation, data-governance requirements, human oversight, and deployment model.
Do not assume
That AI-assisted image analysis replaces clinical validation, a pathologist or clinician, or applies across every imaging modality.
Reagents, raw materials, or research inputs

Diagnostic-component or development supply partner

Finland and Denmark

Publicly stated scope
Start with Medix Biochemica, PentaBase, or MethylDetect when the need is diagnostic raw material, qPCR chemistry, or research-stage methylation input rather than a finished clinical test.
Confirm first
Research-use versus IVD-grade requirements, lot consistency, supply assurance, documentation, assay transfer, intellectual-property terms, and the downstream regulatory plan.
Do not assume
That a reagent or component supplier is the legal manufacturer of a finished clinical diagnostic or carries the final regulatory responsibility.
Numbers

Quick numbers

Diagnostics operators47Across 10 countries the directory covers
Highest country countFinland (9)Molecular IVD, AI pathology, point-of-care, wearables
Liquid biopsy cluster7 operatorsSweden + Denmark + Germany + Norway (plus 2 adjacent)
Digital pathology AI3 operatorsAiforia (FI), Visiopharm (DK), Ligence (LT)
Analysis

Finland: the highest European diagnostics operator count

Finland concentrates 9 diagnostics operators in the directory - the highest single-country diagnostics count. Molecular IVD capacity runs through Abacus Diagnostica (Turku, rapid PCR sample-to-answer), Aidian (Espoo, point-of-care + molecular + microbiology), ArcDia International (Turku, automated near-patient IVD), and Wallac / Revvity (Turku, neonatal and prenatal screening assays at large commercial scale). Biohit (Helsinki) operates gastrointestinal diagnostics and cancer-risk screening. Medix Biochemica (Espoo) supplies IVD raw materials, antibodies, and diagnostic reagents to other manufacturers. On the tech-platform side, Aiforia Technologies (Helsinki) runs AI pathology + digital histopathology services. Bone Index (Kuopio) operates point-of-care pulse-echo ultrasound for osteoporosis; Adamant Health (Kuopio) develops wearable medical devices for Parkinson’s symptom quantification. Finland is the geography the directory surfaces for almost every diagnostic modality at some scale.

Analysis

Liquid biopsy and cancer diagnostics: the European specialty cluster

Liquid biopsy and cancer-monitoring diagnostics is a sector the directory covers in depth. In Sweden, Elypta (Solna) runs metabolomics-based liquid biopsy, Biovica (Uppsala) runs blood-based cancer-monitoring biomarkers, and SAGA Diagnostics (Lund) provides tumor-informed liquid biopsy for molecular residual disease detection. Denmark adds GLX Analytix (Copenhagen, glycomics biomarkers) for the liquid-biopsy core. Germany hosts Hummingbird Diagnostics (Heidelberg, miRNA biomarkers + liquid biopsy for oncology and neurology) and Mainz Biomed (Mainz, colorectal and pancreatic cancer screening). Norway adds Age Labs (Oslo, epigenetic biomarkers). Adjacent cancer-diagnostics operators include 2cureX (Copenhagen, functional drug-sensitivity assays on patient-derived tumour spheroids) and MethylDetect (Aalborg, DNA methylation reagents) - not strict liquid biopsy but closely related. For sponsors running cancer diagnostics programmes, this cluster gives ~7 strict liquid-biopsy operators plus adjacent cancer-monitoring capacity.

Analysis

Digital pathology and AI-assisted image analysis

Digital pathology is one of the most active AI-medical-device verticals in 2026. The European directory surfaces three operators working at clinical scope: Aiforia Technologies in Helsinki runs AI-based pathology + clinical decision support for tissue image analysis; Visiopharm in Horsholm (Denmark) operates digital pathology + tissue-image analysis + precision-diagnostics workflows; Ligence in Kaunas (Lithuania) runs echocardiography analysis software + cardiac imaging AI (adjacent to pathology, in cardiovascular imaging). All three fall under AI Act Article 6(1) as AI safety components of MDR/IVDR medical devices - high-risk obligations apply from August 2027. The EU Biotech Regulation 2026 brief covers the regulatory detail.

Analysis

Molecular diagnostics and IVD infrastructure

Traditional molecular IVD and laboratory diagnostics run through established operators across multiple countries. QIAGEN (Hilden, Germany) is the pan-European molecular-diagnostics and sample-preparation anchor with global distribution. altona Diagnostics (Hamburg, Germany) runs real-time PCR assays for global infectious-disease testing. ORGENTEC Diagnostika (Mainz, Germany) runs autoimmunity + infectious-disease IVD. Spindiag (Freiburg, Germany) operates point-of-care multiplex PCR for respiratory pathogens. PentaBase (Odense, Denmark) runs qPCR chemistry + oligonucleotide diagnostics. Genomtec (Wroclaw, Poland) runs point-of-care isothermal molecular diagnostics using SNAAT cartridge devices. IDL Diagnostics (Stockholm, Sweden) runs tumour-marker and bacteriology IVD. Nordic Biomarker (Umeå) provides coagulation diagnostics and hemostasis reagents. The Polish Wroclaw cluster (Genomtec, Hemolens, Bioavlee) adds point-of-care and microfluidics IVD innovation at clinical-stage.

Analysis

Genetic testing, NIPT, and population-genomics diagnostics

Genetic and population-genomics diagnostics sit alongside clinical IVD. Antegenes (Tartu, Estonia) runs polygenic risk testing and cancer-prevention diagnostics. GenEra (Riga, Latvia) runs medical DNA testing, NIPT (non-invasive prenatal testing), kinship testing, and NGS-based genetic diagnostics. 4bases (Manno, Switzerland) runs CE-IVD NGS reagent kits and clinical sequencing pipelines. intoDNA (Krakow, Poland) runs DNA-break biomarker detection and PARP/DDR biomarker services. Photocure (Oslo, Norway) runs specialty urology diagnostics (Hexvix / Cysview for bladder cancer) at commercial scope. Vitrolife (Gothenburg, Sweden) covers reproductive-health diagnostics and IVF media. For sponsors developing clinical trials that include polygenic or NIPT components, this layer provides EU-based options.

Analysis

National clinical laboratory networks

Three national-scale clinical laboratory networks operate in the directory. Diagnostyka S.A. (Kraków, Poland) runs clinical chemistry, molecular diagnostics, microbiology, and histopathology at national scale across Poland. E. Gulbis Laboratory (Riga, Latvia) operates as Latvia’s nationwide clinical-chemistry and molecular-diagnostics network. Synlab Estonia (Tallinn) operates as the Estonian arm of the pan-European Synlab network. For sponsors running multi-site trials, central-lab partnerships, or biomarker-workflow validation, these three operators provide access to national patient populations and standardised laboratory infrastructure.

Analysis

Regulation: IVD Regulation (IVDR) and AI Act for diagnostics

The EU In Vitro Diagnostic Regulation (IVDR, Regulation (EU) 2017/746) has been in phased application since May 2022 and reached full application for the highest-risk class (Class D) in May 2025, with Class C high-risk reaching full application over 2026–2027. Every CE-IVD operator the directory surfaces is now under the IVDR regime. Separately, the AI Act (Regulation (EU) 2024/1689) applies high-risk obligations to AI embedded in MDR/IVDR medical devices under Article 6(1) from August 2027 (Annex III standalone high-risk systems apply from August 2026). For digital-pathology operators (Aiforia, Visiopharm, Ligence) and AI-enabled liquid-biopsy workflows, both IVDR and AI Act regimes apply concurrently - IVDR from the relevant class date, AI Act from August 2027 for medical-device-embedded AI. The EU Biotech Regulation 2026 brief covers the full regulatory context.

What to watch

What to watch next

IVDR Class C transition through 2026–2027 - capacity of Notified Bodies is the main bottleneck
AI Act Article 6(1) high-risk application (August 2027) for digital-pathology + AI-liquid-biopsy operators embedded in MDR/IVDR devices
Liquid-biopsy commercial progression for Elypta, Biovica, SAGA Diagnostics, Hummingbird
Aiforia Technologies and Visiopharm digital-pathology market consolidation
Polish Wroclaw point-of-care cluster scale-up (Genomtec, Hemolens, Bioavlee)
Wallac / Revvity expansion of neonatal screening platforms
FAQ

Frequently asked questions

Which European countries have the most diagnostics operators in the directory?

By directory count in 2026: Finland (9 operators), Poland (7), Germany (6), Sweden (6), Denmark (5), Lithuania (5), Switzerland (3), Estonia (2), Latvia (2), Norway (2). Finland has the broadest coverage across molecular IVD, AI pathology, point-of-care, and wearables. Sweden and Denmark concentrate liquid-biopsy and cancer-monitoring operators. Germany hosts established IVD anchors (QIAGEN, altona, ORGENTEC). Poland runs the Diagnostyka national laboratory network plus the Wroclaw point-of-care molecular cluster.

Who runs European liquid biopsy programmes?

The directory surfaces roughly 10 European liquid-biopsy and cancer-monitoring operators: Elypta (Solna, Sweden), Biovica (Uppsala, Sweden), SAGA Diagnostics (Lund, Sweden), 2cureX (Copenhagen, Denmark), GLX Analytix (Copenhagen, Denmark), MethylDetect (Aalborg, Denmark), Hummingbird Diagnostics (Heidelberg, Germany), Mainz Biomed (Mainz, Germany), Age Labs (Oslo, Norway). Each operates at a different modality + cancer-type focus - methylation, methyl + miRNA, CTC-based, metabolomics, tumour-informed MRD, drug-sensitivity functional assays, or glycomics.

What European operators offer AI-based digital pathology?

Aiforia Technologies (Helsinki, Finland) operates AI pathology + clinical decision support with a histopathology focus. Visiopharm (Horsholm, Denmark) runs tissue image analysis + precision-diagnostics workflows for pathology. Ligence (Kaunas, Lithuania) operates echocardiography analysis software + cardiac imaging AI - adjacent-modality rather than tissue pathology but still AI-assisted clinical diagnostics. All three are affected by the AI Act Article 6(1) high-risk obligations applying from August 2027 for AI embedded in MDR/IVDR medical devices.

Can I run a national-scale clinical trial through a European diagnostics laboratory?

Yes. Three directory operators provide national-scale laboratory infrastructure: Diagnostyka S.A. (Poland, headquartered in Kraków with national branches), E. Gulbis Laboratory (Latvia, nationwide), and Synlab Estonia (Tallinn, part of the pan-European Synlab network). Pan-European central-lab work typically routes through Synlab’s wider European footprint, plus operators like Vitrolife (reproductive-health diagnostics across Europe) for specialised trial work.

How does IVDR affect diagnostics operators in 2026?

The EU In Vitro Diagnostic Regulation (IVDR, Regulation (EU) 2017/746) has been in phased application since May 2022, reached full application for Class D devices in May 2025, and continues rolling into Class C (high-risk) over 2026–2027. Every CE-IVD operator the directory surfaces runs under IVDR. For AI-enabled diagnostics embedded in MDR/IVDR devices, the AI Act Article 6(1) high-risk obligations apply from August 2027; Annex III standalone high-risk AI systems apply from August 2026. The EU Biotech Regulation 2026 brief covers the regulatory detail.

Methodology note

Sources and interpretation

Sources: verified Memel Biotech directory entries for every diagnostics operator, official company disclosures, EU IVDR + AI Act regulatory materials, and editorial comparison against country-landscape coverage. The directory entry for each operator links to the authoritative company sources.

Disclaimer

Use limits

This brief is an editorial map of visible European diagnostics activity in 2026. It does not rank operators, certify any regulatory status beyond public disclosures, or disclose non-public capacity information - sponsors should verify directly with each operator before engagement.

Primary sources

Source list

EUR-Lex: IVDR (Regulation (EU) 2017/746)EUR-Lex: AI Act (Regulation (EU) 2024/1689)QIAGEN corporate overviewAiforia TechnologiesVisiopharm digital pathology
Related pages

Related directory records

Verification methodologyLithuania biotech page (LT)
Briefs

Continue through related topics.

A useful brief should help people move into related records, cities, categories, and methodology pages without falling back into generic template language.

All briefsDirectory home